CELLDEX THERAPEUTICS INC (CLDX) Stock Fundamental Analysis
USA - NASDAQ:CLDX - US15117B2025 - Common Stock
26 USD
+0.45 (+1.76%)
25.9 USD
-0.1 (-0.38%)
We assign a fundamental rating of 4 out of 10 to CLDX. CLDX was compared to 533 industry peers in the Biotechnology industry. While CLDX has a great health rating, there are worries on its profitability. While showing a medium growth rate, CLDX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year CLDX has reported negative net income.
CLDX had a negative operating cash flow in the past year.
CLDX had negative earnings in each of the past 5 years.
CLDX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -28.83%, CLDX is in the better half of the industry, outperforming 68.11% of the companies in the same industry.
Looking at the Return On Equity, with a value of -30.46%, CLDX is in the better half of the industry, outperforming 77.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.83% | ||
| ROE | -30.46% | ||
| ROIC | N/A |
ROA(3y)-27.38%
ROA(5y)-24.67%
ROE(3y)-29.51%
ROE(5y)-26.78%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CLDX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CLDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CLDX has more shares outstanding
Compared to 5 years ago, CLDX has more shares outstanding
There is no outstanding debt for CLDX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CLDX has an Altman-Z score of 24.59. This indicates that CLDX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 24.59, CLDX belongs to the best of the industry, outperforming 92.50% of the companies in the same industry.
There is no outstanding debt for CLDX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 24.59 |
ROIC/WACCN/A
WACC8.78%
2.3 Liquidity
CLDX has a Current Ratio of 19.67. This indicates that CLDX is financially healthy and has no problem in meeting its short term obligations.
CLDX has a Current ratio of 19.67. This is amongst the best in the industry. CLDX outperforms 95.12% of its industry peers.
A Quick Ratio of 19.67 indicates that CLDX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 19.67, CLDX belongs to the best of the industry, outperforming 95.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 19.67 | ||
| Quick Ratio | 19.67 |
3. Growth
3.1 Past
The earnings per share for CLDX have decreased by -9.85% in the last year.
Looking at the last year, CLDX shows a very negative growth in Revenue. The Revenue has decreased by -30.27% in the last year.
CLDX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.48% yearly.
EPS 1Y (TTM)-9.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.41%
Revenue 1Y (TTM)-30.27%
Revenue growth 3Y14.72%
Revenue growth 5Y14.48%
Sales Q2Q%-70.78%
3.2 Future
The Earnings Per Share is expected to grow by 15.96% on average over the next years. This is quite good.
CLDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 148.65% yearly.
EPS Next Y-45.05%
EPS Next 2Y-31.61%
EPS Next 3Y-19.81%
EPS Next 5Y15.96%
Revenue Next Year-47.04%
Revenue Next 2Y-30.15%
Revenue Next 3Y58.02%
Revenue Next 5Y148.65%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CLDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CLDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as CLDX's earnings are expected to decrease with -19.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-31.61%
EPS Next 3Y-19.81%
5. Dividend
5.1 Amount
No dividends for CLDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
26
+0.45 (+1.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners111.29%
Inst Owner Change3.29%
Ins Owners0.21%
Ins Owner Change-0.44%
Market Cap1.73B
Revenue(TTM)5.79M
Net Income(TTM)-199.61M
Analysts80.91
Price Target54.5 (109.62%)
Short Float %11.34%
Short Ratio7.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.28%
Min EPS beat(2)-5.18%
Max EPS beat(2)2.62%
EPS beat(4)3
Avg EPS beat(4)2.34%
Min EPS beat(4)-5.18%
Max EPS beat(4)6.71%
EPS beat(8)5
Avg EPS beat(8)1.72%
EPS beat(12)9
Avg EPS beat(12)2.67%
EPS beat(16)9
Avg EPS beat(16)-0.68%
Revenue beat(2)0
Avg Revenue beat(2)-31.89%
Min Revenue beat(2)-34.86%
Max Revenue beat(2)-28.92%
Revenue beat(4)2
Avg Revenue beat(4)54.29%
Min Revenue beat(4)-34.86%
Max Revenue beat(4)277.69%
Revenue beat(8)5
Avg Revenue beat(8)108.94%
Revenue beat(12)8
Avg Revenue beat(12)121.84%
Revenue beat(16)8
Avg Revenue beat(16)73.39%
PT rev (1m)-5.02%
PT rev (3m)-8.8%
EPS NQ rev (1m)0.35%
EPS NQ rev (3m)-0.64%
EPS NY rev (1m)0.12%
EPS NY rev (3m)-0.91%
Revenue NQ rev (1m)-2.24%
Revenue NQ rev (3m)-6.16%
Revenue NY rev (1m)-1.76%
Revenue NY rev (3m)-6.75%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 298.16 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.63 | ||
| P/tB | 2.75 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.01
EYN/A
EPS(NY)-4.24
Fwd EYN/A
FCF(TTM)-2.84
FCFYN/A
OCF(TTM)-2.8
OCFYN/A
SpS0.09
BVpS9.87
TBVpS9.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.83% | ||
| ROE | -30.46% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-27.38%
ROA(5y)-24.67%
ROE(3y)-29.51%
ROE(5y)-26.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 68.58% | ||
| Cap/Sales | 39.61% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 19.67 | ||
| Quick Ratio | 19.67 | ||
| Altman-Z | 24.59 |
F-Score2
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)61.32%
Cap/Depr(5y)52.82%
Cap/Sales(3y)43.76%
Cap/Sales(5y)35.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.41%
EPS Next Y-45.05%
EPS Next 2Y-31.61%
EPS Next 3Y-19.81%
EPS Next 5Y15.96%
Revenue 1Y (TTM)-30.27%
Revenue growth 3Y14.72%
Revenue growth 5Y14.48%
Sales Q2Q%-70.78%
Revenue Next Year-47.04%
Revenue Next 2Y-30.15%
Revenue Next 3Y58.02%
Revenue Next 5Y148.65%
EBIT growth 1Y-43.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.28%
EBIT Next 3Y-19.26%
EBIT Next 5YN/A
FCF growth 1Y-64.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.18%
OCF growth 3YN/A
OCF growth 5YN/A
CELLDEX THERAPEUTICS INC / CLDX FAQ
Can you provide the ChartMill fundamental rating for CELLDEX THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 4 / 10 to CLDX.
What is the valuation status for CLDX stock?
ChartMill assigns a valuation rating of 0 / 10 to CELLDEX THERAPEUTICS INC (CLDX). This can be considered as Overvalued.
What is the profitability of CLDX stock?
CELLDEX THERAPEUTICS INC (CLDX) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for CLDX stock?
The Earnings per Share (EPS) of CELLDEX THERAPEUTICS INC (CLDX) is expected to decline by -45.05% in the next year.